Stay updated on Selonsertib for NASH F3 Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Selonsertib for NASH F3 Fibrosis Clinical Trial page.

Latest updates to the Selonsertib for NASH F3 Fibrosis Clinical Trial page
- Check2 days agoChange DetectedAdded Non-alcoholic fatty liver disease and related topics (including MedlinePlus Genetics) and updated the site revision to v3.4.2; removed the government funding lapse notice (and the prior v3.4.1 revision). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check9 days agoChange DetectedA government funding notice banner was added and the page revision version updated. A non-critical glossary term related to nonalcoholic fatty liver disease was removed.SummaryDifference0.2%

- Check16 days agoChange DetectedAdded UI elements and labels: Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0; removed Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check24 days agoChange DetectedAdded related topic 'Non-alcoholic fatty liver disease' and related topic 'MedlinePlus Genetics'. Updated Revision from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check45 days agoChange DetectedThe Related Topics section no longer lists 'Non-alcoholic fatty liver disease' and 'MedlinePlus Genetics' for this study; these are ancillary topics and do not affect core study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedA single 'Locations' section now lists all study sites across the US, Canada, Australia, and India, consolidating what were previously separate location blocks.SummaryDifference1%

Stay in the know with updates to Selonsertib for NASH F3 Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selonsertib for NASH F3 Fibrosis Clinical Trial page.